These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 2832717)

  • 1. National Childhood Vaccine Injury Act: requirements for permanent vaccination records and for reporting of selected events after vaccination.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1988 Apr; 37(13):197-200. PubMed ID: 2832717
    [No Abstract]   [Full Text] [Related]  

  • 2. Leads from the MMWR. National Childhood Vaccine Injury Act: requirements for permanent vaccination records and for reporting of selected events after vaccination.
    JAMA; 1988 May; 259(17):2527-8. PubMed ID: 2833628
    [No Abstract]   [Full Text] [Related]  

  • 3. Guillain-Barré syndrome after vaccination in United States: data from the Centers for Disease Control and Prevention/Food and Drug Administration Vaccine Adverse Event Reporting System (1990-2005).
    Souayah N; Nasar A; Suri MF; Qureshi AI
    J Clin Neuromuscul Dis; 2009 Sep; 11(1):1-6. PubMed ID: 19730016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. National childhood vaccine injury act. Requirements for permanent vaccination records and for reporting of selected events after vaccination. National Vaccine Program, Centers for Disease Control.
    Ohio Med; 1988 Sep; 84(9):754-6. PubMed ID: 3222033
    [No Abstract]   [Full Text] [Related]  

  • 5. The Vaccine Safety Datalink project.
    DeStefano F;
    Pharmacoepidemiol Drug Saf; 2001; 10(5):403-6. PubMed ID: 11802585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse events following immunization.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1985 Jan; 34(3):43-7. PubMed ID: 2981396
    [No Abstract]   [Full Text] [Related]  

  • 7. What you should know about FDA-USP Drug Product Problem Reporting Program.
    McGinnis DM
    Pharm Times; 1986 Apr; 52(4):101-4, 109. PubMed ID: 10276472
    [No Abstract]   [Full Text] [Related]  

  • 8. Vaccine Adverse Event Reporting System--United States.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1990 Oct; 39(41):730-3. PubMed ID: 2120567
    [No Abstract]   [Full Text] [Related]  

  • 9. Adverse drug reaction reporting.
    Bosco LA
    Am J Gastroenterol; 1987 Apr; 82(4):356-7. PubMed ID: 3565343
    [No Abstract]   [Full Text] [Related]  

  • 10. Vaccine adverse event reporting: the importance of follow-up.
    Varricchio F
    Expert Rev Vaccines; 2005 Aug; 4(4):445-8. PubMed ID: 16117700
    [No Abstract]   [Full Text] [Related]  

  • 11. Delegations of authority and organization; National Childhood Vaccine Injury Act of 1986--FDA. Final rule.
    Fed Regist; 1993 Apr; 58(61):17105-6. PubMed ID: 10125232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In the heat of a signal: responding to a vaccine safety signal for febrile seizures after 2010-11 influenza vaccine in young children, United States.
    Broder KR; Martin DB; Vellozzi C
    Vaccine; 2012 Mar; 30(11):2032-4. PubMed ID: 22361305
    [No Abstract]   [Full Text] [Related]  

  • 13. An analysis of the reactivity of vaccines administered in Texas from 1991 through 1999.
    Geier DA; Geier MR
    Tex Med; 2002 Jul; 98(7):50-4. PubMed ID: 12134752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revised ADR report permits internal review of drug experience.
    Jeffrey LP
    Pharm Times; 1986 Dec; 52(12):48-50. PubMed ID: 10317827
    [No Abstract]   [Full Text] [Related]  

  • 15. Standards for child and adolescent immunization practices. National Vaccine Advisory Committee.
    National Vaccine Advisory Committee
    Pediatrics; 2003 Oct; 112(4):958-63. PubMed ID: 14523192
    [No Abstract]   [Full Text] [Related]  

  • 16. Congress examines childhood vaccine safety.
    Dove A
    Nat Med; 1999 Sep; 5(9):970. PubMed ID: 10471261
    [No Abstract]   [Full Text] [Related]  

  • 17. Reporting adverse drug therapy results.
    Pa Med; 1990 Jun; 93(6):29. PubMed ID: 2367135
    [No Abstract]   [Full Text] [Related]  

  • 18. Quality assessment of nonanthrax vaccination data in the Defense Medical Surveillance System (DMSS), 1998-2004.
    Davila JC; Payne DC; Zhang Y; Rose CE; Aranas A; Hill AN; Ruscio B; McNeil MM
    Vaccine; 2008 Mar; 26(12):1577-84. PubMed ID: 18295379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of vaccination clinics; user fees for investigational new drug (IND) influenza vaccine services and vaccines. Interim final rule and request for comments.
    Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS)
    Fed Regist; 2005 Jan; 70(15):3490-3. PubMed ID: 15669145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preface to supplement. Active surveillance of vaccine safety in the US Food and Drug Administration's Mini-Sentinel program: identification of exposures and outcomes.
    Vaccine; 2013 Dec; 31 Suppl 10():K1. PubMed ID: 24331068
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.